- Home
- CYTK
as 11-21-2024 9:43am EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 6.0B | IPO Year: | 2004 |
| Target Price: | $83.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.68 - $110.25 | Next Earning Date: | 11-06-2024 |
| Revenue: | $3,219,000 | Revenue Growth: | -58.81% |
| Revenue Growth (this year): | -12.99% | Revenue Growth (next year): | 911.39% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Blum Robert I | CYTK | President & CEO | Nov 18 '24 | Sell | $50.55 | 5,000 | $252,750.00 | 397,456 | |
| Blum Robert I | CYTK | President & CEO | Nov 1 '24 | Sell | $51.63 | 5,000 | $258,150.00 | 397,456 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 30 '24 | Sell | $51.92 | 7,300 | $378,930.00 | 116,920 | |
| WIERENGA WENDALL | CYTK | Director | Oct 28 '24 | Sell | $52.25 | 4,452 | $232,617.00 | 24,559 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 15 '24 | Sell | $54.19 | 7,300 | $395,554.00 | 116,920 | |
| Blum Robert I | CYTK | President & CEO | Oct 9 '24 | Sell | $55.61 | 5,000 | $278,050.00 | 397,456 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Oct 1 '24 | Sell | $52.10 | 7,300 | $380,297.00 | 116,920 | |
| Blum Robert I | CYTK | President & CEO | Sep 30 '24 | Sell | $52.14 | 5,000 | $260,700.00 | 397,456 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Sep 17 '24 | Sell | $56.77 | 7,300 | $414,401.00 | 116,920 | |
| Blum Robert I | CYTK | President & CEO | Sep 16 '24 | Sell | $55.99 | 5,000 | $279,950.00 | 397,456 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
BioPharma Dive
2 days ago
Astellas application rejected by FDA; Cytokinetics strikes licensing deal with Bayer
MT Newswires
2 days ago
Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan
GuruFocus.com
2 days ago
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan
GuruFocus.com
2 days ago
Cytokinetics and Bayer Partner to Expand Aficamten's Reach in Japan
Reuters
2 days ago
Bayer acquires rights to Cytokinetics' heart drug in Japan
GlobeNewswire
2 days ago
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
GlobeNewswire
5 days ago
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.